Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (493)	4/19/1999 3:38:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1494

Jeffrey, I agree that this is a fair and responsible deal for existing shareholders. Considering adding to my position, but that spread is horrible. First order of business if the trials are successful and/or they get a partner will be to get back on the NASDAQ small cap market. Peter

To: BRAVEHEART who wrote (493)	4/19/1999 3:41:00 PM
From: Apache Indian	Read Replies (1) \| Respond to of 1494

what timing!!

To: BRAVEHEART who wrote (493)	4/20/1999 10:08:00 AM
From: Apache Indian	Read Replies (2) \| Respond to of 1494

Umm..perhaps NOT the "Best Possible Scenario". In my mind, if the success of Memantine has become a foregone conclusion, and the only hurdle the company repeatedly faces is $, $$, more $$$ then maybe its time to simply resolve this matter once and for all and strike a deal with some marketing firm. This drop at a time financing DOES dilute our stake in the company. We are talking about 2.2 million additional shares + about 800,000 in options to buy the shares at $1. Thats approx 3 million additional shares of NTII some company would have to buy (if we are talking about a buyout) Thats about 30 percent dilution for only 1.1 million in the company coffers (+2 million if options were exercised). Thats some good deaL~! I think NTI is selling the company out in bits and pieces, first the patents and now the shares, their vulnerable poisiton had them striking that deal with Merz, which might now make NTI uninteresting to any big Pharma, only medium sized companies wanting an additional drug in their portfolio might now be interested in NTI because of the complexity in the deal with Merz, and now we are making the price tag richer by diluting the shares and gaining almost nothing,, just think about this , what does the company get for 1.1 million, 5 months of operation, and what does NTI accomplish in 5 months, NOTHING, ABSOLUTELY NOTHING (I've seen it for months now) , at this rate what You and Me will get tomorrow will be nothing more a premuim that we would have got today or much yet before selling those rights away to Merz. They are simply wasting my time!